Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.

MLA

Yan Zhu, et al. “Dual PI3K/MTOR Inhibitor BEZ235 Exerts Extensive Antitumor Activity in HER2-Positive Gastric Cancer.” BMC Cancer, vol. 15, Nov. 2015, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-015-1900-y.

APA

Yan Zhu, Tiantian Tian, Jianling Zou, Qiwei Wang, Zhongwu Li, Yanyan Li, Xijuan Liu, Bin Dong, Na Li, Jing Gao, Lin Shen, Zhu, Y., Tian, T., Zou, J., Wang, Q., Li, Z., Li, Y., Liu, X., Dong, B., & Li, N. (2015). Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer, 15, 1–10. https://doi.org/10.1186/s12885-015-1900-y

Chicago

Yan Zhu, Tiantian Tian, Jianling Zou, Qiwei Wang, Zhongwu Li, Yanyan Li, Xijuan Liu, et al. 2015. “Dual PI3K/MTOR Inhibitor BEZ235 Exerts Extensive Antitumor Activity in HER2-Positive Gastric Cancer.” BMC Cancer 15 (November): 1–10. doi:10.1186/s12885-015-1900-y.